[go: up one dir, main page]

WO2006017369A3 - Use of a farnesyl transferase inhibitor in the treatment of viral infections - Google Patents

Use of a farnesyl transferase inhibitor in the treatment of viral infections Download PDF

Info

Publication number
WO2006017369A3
WO2006017369A3 PCT/US2005/025176 US2005025176W WO2006017369A3 WO 2006017369 A3 WO2006017369 A3 WO 2006017369A3 US 2005025176 W US2005025176 W US 2005025176W WO 2006017369 A3 WO2006017369 A3 WO 2006017369A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
farnesyl transferase
viral infections
transferase inhibitor
farnesyl
Prior art date
Application number
PCT/US2005/025176
Other languages
French (fr)
Other versions
WO2006017369A2 (en
Inventor
Steven Zeichner
Vyjayanthi Krishnan
Original Assignee
Us Gov Health & Human Serv
Steven Zeichner
Vyjayanthi Krishnan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Steven Zeichner, Vyjayanthi Krishnan filed Critical Us Gov Health & Human Serv
Publication of WO2006017369A2 publication Critical patent/WO2006017369A2/en
Publication of WO2006017369A3 publication Critical patent/WO2006017369A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Treatment of cells or humans carrying or infected with a virus capable of causing an immunodeficiency disease by administration of one or more compounds that inhibit farnesyl transferase.
PCT/US2005/025176 2004-07-13 2005-07-13 Use of a farnesyl transferase inhibitor in the treatment of viral infections WO2006017369A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58777104P 2004-07-13 2004-07-13
US60/587,771 2004-07-13

Publications (2)

Publication Number Publication Date
WO2006017369A2 WO2006017369A2 (en) 2006-02-16
WO2006017369A3 true WO2006017369A3 (en) 2006-11-23

Family

ID=35839815

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/025176 WO2006017369A2 (en) 2004-07-13 2005-07-13 Use of a farnesyl transferase inhibitor in the treatment of viral infections

Country Status (1)

Country Link
WO (1) WO2006017369A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027929A1 (en) * 1997-12-04 1999-06-10 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5919780A (en) * 1995-06-16 1999-07-06 Warner Lambert Company Tricyclic inhibitors of protein farnesyltransferase
WO2002024686A2 (en) * 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919780A (en) * 1995-06-16 1999-07-06 Warner Lambert Company Tricyclic inhibitors of protein farnesyltransferase
WO1999027929A1 (en) * 1997-12-04 1999-06-10 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO2002024686A2 (en) * 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives

Also Published As

Publication number Publication date
WO2006017369A2 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
CL2007003686A1 (en) COMPOUNDS DERIVED FROM INDOL WITH UNITED RING IN POSITIONS 4,5; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND TO TREAT A VIRAL INFECTION.
WO2008003149A3 (en) Substituted pteridines for the treatment and prevention of viral infections
WO2007041487A3 (en) Viral peptides and their use to inhibit viral infections against viruses of the flaviridae family
WO2008045238A3 (en) Stabilized therapeutic small helical antiviral peptides
WO2005077050A3 (en) Hiv integrase inhibitors
TN2010000137A1 (en) Spiropyrrolidines and their use against hcv and hiv infection
ECSP077252A (en) Methods to treat hepatitis C
CL2009000305A1 (en) Compounds derived from 2-aryl-substituted-1-benzofuran-3-carboxamide, ns5b polymerase inhibitors; pharmaceutical composition; and its use in the treatment of a disease caused by the hepatitis c virus (hcv).
CL2007003250A1 (en) COMPOUNDS DERIVED FROM ISOQUINOLINE, INHIBITORS OF THE HEPATITIS C VIRUS; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF AN HCV INFECTION.
NO20091258L (en) Entantiomerically pure phosphoindoles as HIV inhibitors
CL2013000727A1 (en) Compounds derived from imidazo [1,2-f] [1,2,4] triazinyl nucleosides; pharmaceutical composition that includes them; and its use for the treatment of a flaviviridae virus infection, particularly hepatitis c virus infections.
ATE534652T1 (en) PHOSPHONO-PENT-2-EN-1-YL NUCLEOSIDES AND ANALOGS
EA201000777A1 (en) Inhibitors of Human Immunodeficiency Virus Replication
WO2009055335A3 (en) Hcv protease inhibitors
WO2008115281A3 (en) Compounds for treating viral infections
CA2862755A1 (en) Antiviral compounds with a dibenzooxaheterocycle moiety
WO2007019098A3 (en) Hiv integrase inhibitors
CL2007002671A1 (en) COMPOUNDS DERIVED FROM OCTAHIDRO-PIRROLO [3,4-C] PIRROL; PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT; AND USE OF THE COMPOUND IN THE TREATMENT OF HIV, AIDS OR ARC.
NO20071871L (en) Phosphoindoles as HIV inhibitors.
IL203873A0 (en) Novel targets and compounds for therapeutic intervention of hiv infection
WO2007065007A3 (en) Treatment of viral infections
WO2010052559A8 (en) Cycloundecadepsipeptide compounds and use of said compounds as a medicament
WO2007076091A3 (en) Treatment of viral infections using a tissue factor inhibitor
WO2009014417A3 (en) An antiviral composition
AR052165A1 (en) HEPATITIS C TREATMENT IN THE ASIAN POPULATION

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase